T CELL RECEPTORS

The present invention relates to T cell receptors (TCRs) that the property of binding to EVDPIGHLY (SEQ ID No: 1) HLA-A1 complex and comprise a TCR alpha chain variable domain and a TCR beta chain variable domain. The EVDPIGHLY peptide is derived from the MAGE-3 protein which is expressed in many tu...

Full description

Saved in:
Bibliographic Details
Main Authors VUIDEPOT, ANNELISE BRIGITTE, JAKOBSEN, BENT KARSTEN, LIDDY, NATHANIEL ROSS, MOLLOY, PETER EAMON
Format Patent
LanguageEnglish
French
Published 28.03.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to T cell receptors (TCRs) that the property of binding to EVDPIGHLY (SEQ ID No: 1) HLA-A1 complex and comprise a TCR alpha chain variable domain and a TCR beta chain variable domain. The EVDPIGHLY peptide is derived from the MAGE-3 protein which is expressed in many tumour types, including melanomas, and other solid tumours such as Head and Neck Squamous Cell, lung, bladder, gastric, prostate, colorectal and esophageal carcimomas. Also provided are nucleic acids encoding such TCRs, cells presenting such TCRs and pharmaceutical compositions comprising such TCRs. La présente invention concerne des récepteurs de lymphocytes T (TCR) qui ont la propriété de liaison à un complexe HLA-A1 EVDPIGHLY (SEQ ID No :1) et comprennent un domaine variable de chaîne alpha de TCR et un domaine variable de chaîne bêta de TCR. Le peptide EVDPIGHLY est issu de la protéine MAGE-3 qui est exprimée dans de nombreux types de tumeur, comprenant des mélanomes, et d'autres tumeurs solides, telles que des carcinomes des Cellules Squameuses de la Tête et du Cou, du poumon, de la vessie, de l'estomac, de la prostate, colorectaux et oesophagiques. L'invention concerne également des acides nucléiques codant pour de tels TCR, des cellules présentant de tels TCR, et des compositions pharmaceutiques comprenant de tels TCR.
Bibliography:Application Number: WO2012GB52322